Zydus Cadila gets USFDA nod for chemotherapy drug
New Delhi : Drug firm Zydus Cadila said it has received approval from the US health regulator to market methotrexate tablets, a chemotherapy drug, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market the drug, Zydus Cadila said in a regulatory filing.
The drug will be produced at the group's manufacturing facility in Ahmedabad.
The Gujarat-based group now has more than 105 approvals and has so far filed nearly 275 abbreviated new drug applications (ANDAs) since 2003-04.
Shares of Cadila Healthcare, the group's listed entity, Wednesday ended at Rs 356.35 apiece on the BSE, up 1.87 per cent from previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd